Our Priorities
Dedicated to Developing New Treatment Options Safely and Responsibly
At FibroGen, we are dedicated to advancing first-in-class medicines that have the potential to provide new and effective treatment options to the patients who need them.
Before a new treatment can be made widely available, it must go through rigorous testing involving extensive preclinical and clinical studies. These studies are carefully conducted within guidelines set by the U.S. Food and Drug Administration (FDA) and corresponding regulatory authorities outside the U.S. The purpose of clinical trials is to evaluate the safety and effectiveness of promising new therapeutics. Patients who participate in clinical trials may gain access to investigational treatments before they are widely available, and play an important role in helping researchers and clinicians answer key questions about potential new products.
FG-3246 Trials
FG-3246 is a potential first-in-class fully human antibody-drug conjugate (ADC) targeting CD46 being developed for metastatic castration-resistant prostate cancer and with the potential for additional trials targeting other CD46 expressing cancers.
Roxadustat Trials
Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and patients not on dialysis. Roxadustat is in Phase 3 clinical development in China for treatment of chemotherapy-induced anemia (CIA).
We believe that participating in our clinical trials is the best way for patients to potentially access our investigational medicines prior to regulatory approval. Please review the information found on this website as well as at Should you locate a clinical study with a participating site that you are interested in, you or your physician may contact that site directly to request more information about enrollment.
​
In exceptional cases, when patient participation in a clinical trial is not possible, and there are no other therapies available to treat the patient’s disease or condition, the patient’s physician may request access to one of our investigational drugs on humanitarian grounds. These requests are sometimes referred to as “expanded access” or “compassionate use”, though other terms may be used for the same request. For our policy on expanded access or for more information, please contact us here.